A new time-saving method for determining nitrogen in biologic material.

M Dambacher; A Gubler; H G Haas

Home/Archive/PubMed

PubMed · 5663457

A new time-saving method for determining nitrogen in biologic material.

M Dambacher·A Gubler·H G Haas

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Feces Humans Methods Nitrogen Spectrophotometry Time Factors Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M Dambacher, A Gubler, H G Haas. 1968. A new time-saving method for determining nitrogen in biologic material.. https://pubmed.ncbi.nlm.nih.gov/5663457/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Development and validation of a novel LC-MS/MS method for simultaneous quantification of fidaxomicin and metabolite (OP-1118) from feces for gut pharmacobiome studies.

Fidaxomicin is a first-line antibiotic for treating Clostridioides difficile infection. While it has low systemic absorption and reaches high colonic concentrations, it is hydrolyzed to a less active metabolite, OP-1118. Few studies have completely described critical experimental details of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for quantifying fecal fidaxomicin and OP-1118. This study developed and validated a simple, fast, and sensitive LC-MS/MS method to quantify fidaxomicin and OP-1118 in human and mouse feces. This method simplified fecal sample preparation without the use of solid phase extraction and optimized LC-MS/MS parameters. A broad working range (0.3-1000 ng/ml) in both diluted human and murine fecal matrices was achieved with good intra- and inter-day accuracy (93-107%), precision (1-7%), and recovery (70-105%) as well as little IS-normalized matrix effects. This method was utilized to quantify fidaxomicin and OP-1118 in human and murine fecal samples. This novel method was simple, fast, sensitive, and accurate in analyzing fecal fidaxomicin and OP-1118 and could be deployed to facilitate gut pharmacobiome research.

Feces↗

PubMed2024

Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer.

There is a high unmet need for early detection approaches for diffuse gastric cancer (DGC). We examined whether the stool proteome of mouse models of gastric cancer (GC) and individuals with hereditary diffuse gastric cancer (HDGC) have utility as biomarkers for early detection. Proteomic mass spectrometry of the stool of a genetically engineered mouse model driven by oncogenic KrasG12D and loss of p53 and Cdh1 in gastric parietal cells [known as Triple Conditional (TCON) mice] identified differentially abundant proteins compared with littermate controls. Immunoblot assays validated a panel of proteins, including actinin alpha 4 (ACTN4), N-acylsphingosine amidohydrolase 2 (ASAH2), dipeptidyl peptidase 4 (DPP4), and valosin-containing protein (VCP), as enriched in TCON stool compared with littermate control stool. Immunofluorescence analysis of these proteins in TCON stomach sections revealed increased protein expression compared with littermate controls. Proteomic mass spectrometry of stool obtained from patients with HDGC with CDH1 mutations identified increased expression of ASAH2, DPP4, VCP, lactotransferrin (LTF), and tropomyosin-2 relative to stool from healthy sex- and age-matched donors. Chemical inhibition of ASAH2 using C6 urea ceramide was toxic to GC cell lines and GC patient-derived organoids. This toxicity was reversed by adding downstream products of the S1P synthesis pathway, which suggested a dependency on ASAH2 activity in GC. An exploratory analysis of the HDGC stool microbiome identified features that correlated with patient tumors. Herein, we provide evidence supporting the potential of analyzing stool biomarkers for the early detection of DGC. Prevention Relevance: This study highlights a novel panel of stool protein biomarkers that correlate with the presence of DGC and has potential use as early detection to improve clinical outcomes.

Feces↗

PubMed1998

Quantification of fecal alpha 1-antitrypsin excretion for assessment of inflammatory bowel diseases.

Determination of fecal excretion of the serum proteinase inhibitor alpha(1)-antitrypsin (AAT) is established for quantification of intestinal protein loss. It was demonstrated to be increased both in quiescent and in active inflammatory bowel diseases (IBD, Crohn's disease and ulcerative colitis). The (patho)physiological rationale for measuring fecal AAT excretion and its role in the diagnostic and prognostic assessment of these disorders will be critically reviewed. Experimental and clinical data were selected from computerized MEDLINE literature search, manual review of bibliographies, and personal experiences of the authors. In IBD patients, fecal AAT excretion corresponds to gross assessment of clinical disease activity, endoscopic degree of intestinal inflammation, and any response to treatment. It appears to be an early indicator of subclinical bowel disease and its imminent exacerbation. However, there is neither strict correlation to summarizing clinical disease activity indices, nor to extent or location of intestinal inflammation. Fecal AAT excretion was also found to be elevated in active pouchitis, and to correlate to its severity. In summary, estimation of fecal AAT excretion is a sensitive, but non-specific parameter reflecting enteric inflammation in IBD individuals. It proved to be an independent supplementary variable for monitoring their intestinal disease activity, with some predictive value for their forthcoming clinical course.

Feces↗